Cot Modulator Compounds for Targeted Protein Activity Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective agents to modulate the expression or activity of Cot protein, which is involved in inflammatory diseases and cancer, leading to unaddressed conditions such as rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, diabetes, sepsis, psoriasis, and graft rejection.
Innovation Solution
Development of compounds that modulate the expression or activity of Cot protein, represented by specific chemical structures, for use in pharmaceutical compositions to treat diseases mediated by Cot.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current therapies are used, then existing treatment options are available, but effective modulation of Cot protein expression or activity is lacking
Solution Approach 1:
The patent employs parameter changes by developing small molecule compounds with specific chemical structures (Formula I) that can modulate Cot protein activity. The compounds feature variable substituents (R1-R6, Z1-Z8) that can be optimized to achieve desired therapeutic effects, representing systematic parameter optimization to overcome the lack of effective Cot modulators in current therapies
2Reliability
If Cot protein activity is modulated, then therapeutic benefits for inflammatory diseases and cancer are achieved, but new compound development and pharmaceutical composition formulation are required
Solution Approach 1:
The patent segments the therapeutic approach into distinct components: (1) core compound structures of Formula I with defined variable regions, (2) pharmaceutical compositions containing these compounds, and (3) methods of use for treating specific diseases. This segmentation allows systematic development and optimization of each component independently
Solution Approach 2:
The patent creates universal solutions by developing compounds that can treat multiple Cot-mediated diseases including inflammatory diseases (rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease, psoriasis), metabolic diseases (diabetes), and cancer. The broad-spectrum applicability reduces the need for disease-specific compound development
Data Source
AI summary
The present disclosure relates generally to modulators of Cot (cancer Osaka thyroid) and methods of use and manufacture thereof.